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Abstract 
Objectives: To investigate the quality of life (QoL) and to characterize patients with atopic 
dermatitis (AD) in Portugal.   
Methods: This was a cross-sectional study, including patients with AD and other eczemas. 
Skindex-29, Skindex-teen and Childhood Atopic Dermatitis Impact Scale (CADIS) were the 
instruments used to assess QoL in adults, teenagers, and children respectively. 
Complementarily, the SF-12 was used and disease severity was evaluated through Patient-
Oriented SCORAD (PO-SCORAD). Odds Ratio (OR) were performed to measure 
associations with QoL. SPSS statistics 95% confidence intervals and values of p<0.05 were 
considered statistically significant. 
Results:162 participants were included, aging 0.5-74 years. We found that 37.3% of AD 
patients consider their disease as disabling and more than half of AD patients feel stigmatized 
by society. The mean Skindex score for AD was 39.68, and 44% patients presented a severe 
QoL impact. “Symptoms” was the most affected category in adults. Moderate to severe AD 
patients were 87% of the sample. Regarding the factors that most influenced worse QoL in 
AD, with increasing age, the Skindex score is likely to increase (OR: 1.03 [95%CI 1.00-
1.06]). “Consider having disability” was also associated, OR: 6.72 (95%CI 2.56-17.63). With 
increasing affected body area and edema, the QoL worsens (OR: 1.07 [95%CI 1.03-1.11] and 
OR: 2.04 [95%CI 1.23-3.40], respectively).   
Conclusions: This is the first study with QoL data about AD patients in Portugal, revealing 
an expected negative impact. More awareness-raising activities are needed to increase 
literacy, decrease the stigma, and consequently to address some impacted factors in AD 
patients’ QoL. 
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Resumen 
Objetivos: investigar la calidad de vida (QoL) y caracterizar a los pacientes con dermatitis 
atópica (AD) en Portugal. 
Métodos: Se trata de un estudio transversal, que incluyó pacientes con AD y otros eczemas. 
Skindex-29, Skindex-teen y ChildhoodAtopic Dermatitis ImpactScale (CADIS) fueron los 
instrumentos utilizados para evaluar la calidad de vida en adultos, adolescentes y niños, 
respectivamente. Además, se utilizó el SF-12 y se evaluó la gravedad de la enfermedad a 
través del SCORAD Orientado por el paciente (PO-SCORAD). Se determinó el Odds Ratio 
(OR) para medir su asociación con QoL. Valores de p <0.05 fueron considerado 
estadísticamente significativos. 
Resultados: se incluyeron 162 participantes, con una edad entre 0,5 a 74 años. El 37.3% de 
los pacientes con AD consideraron que su enfermedad es incapacitante y más de la mitad de 
los pacientes con DA se sienten estigmatizadospor la sociedad. La puntuación media de 
Skindex para AD fue de 39.68 y el 44% de los pacientes presentaron un importante Impacto 
de la QoL. "Síntomas" fue la categoría más afectada en adultos. La DA fue catalogada como 
moderada a severa en el 87% de la muestra. En cuanto a los factores que más influyeron en la 
peor calidad de vida enAD fueron:  1) el aumento con la edad, la puntuación Skindex 
aumenta (OR: 1.03 [IC 95% 1.00-1.06]; 2)también se asoció)"Considerar tener 
discapacidad", OR: 6.72 (IC 95% 2.56-17.63); 3) con el aumento del  área corporal afectada y 
el edema, la calidad de vida empeora (OR: 1.07 [IC 95% 1.03-1.11] yOR: 2.04 [IC 95% 1.23-
3.40], respectivamente). 
Conclusiones: este es el primer estudio con datos de calidad de vida sobre pacientes con DA 
en Portugal y que revela un impacto negativo esperado sobre ésta. Se necesitan más 
actividades de sensibilización para aumentar el conocimiento,disminuir el estigma y, en 
consecuencia, abordar algunos factores afectados en la calidad de vida de los pacientes con 
DA. 
 
Palabras clave: dermatitis atópica, eccema atópico, Portugal, calidad de vida, Skindex. 
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Introduction  
The occurrence of inflammatory chronic diseases is an increasing concern in industrialized 
countries. There is still no definite cure for most chronic conditions and more attention is 
being paid to patient’s limitations, disability, and quality of life (QoL) [1].  
Assessing QoL has led to a better comprehension of the impact of the pathology and is a 
good indicator in decisions regarding the most appropriate treatment for each subject. In 
addition, looking at some issues, the assessment makes it possible to deal with patients more 
effectively. Communication on QoL can also be useful by involving patients in discussions of 
treatment preferences and allow for mutual or shared decision making [2].  
In chronic dermatological diseases, treatments may offer temporary suppression or 
diminution of severity and symptoms [2]. As a result, many patients must cope with the 
impact of their illness throughout life. Skin diseases are sometimes neglected by society and 
continue to receive little attention in global health discussions [3].  
Atopic dermatitis (AD) is a chronic and relapsing inflammatory disease characterized by 
intense pruritus and very sensitive and dry skin [4]. In fact, AD and other types of  eczema 
affect patients’ QoL dramatically due to their impact on a range of factors, including 
psychological, social, physical, and functional (relationships and daily activities) [4, 5].  
Due to a paucity of data, the importance of studying the QoL of Portuguese patients with AD 
is very clear. The aim of this study is to assess patients’ QoL and determine the factors that 
may be associated with their QoL, as well as among patients with other eczemas. As a 
secondary objective, we questioned the patients about the impact in how they feel concerning 
medical community and society in their QoL. 
 
Materials and Methods  
Study design and population 
QUADEP (QUality of Life in Atopic Dermatitis and Eczema in Portugal) is a national, cross-
sectional study performed in Portugal in 2018. Recruitment for the participants was based on 
interviews. Patients’ databases were constructed beforehand with data from a previous 
prevalence study[6]. Of those who accepted to participate in QUADEP, 38.2% completed the 
study. In order to enhance the range of patients enrolled, notices soliciting participants were 
discloses in clinics in Lisbon and posted on websites, available to all country. Additionally, 
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the AD patient association, ADERMAP (AssociaçãoDermatiteAtópica Portugal), assisted in 
the recruitment effort. After a patient’s consent, questionnaires were sent by post or e-mail. In 
addition, for those who agreed, a phone interview to collect additional data was undertaken. 
All subjects provided informed consent prior to participation, and this study was approved by 
the Portuguese Commission of Data Protection (CNPD) before being undertaken. 
Only patients living in Portugal and with Portuguese nationality were considered. A 
participant’s self-reported diagnosis of AD or eczema was also a criterion for inclusion, 
which was assessed through the following question: “Have you ever been diagnosed with AD 
or eczema by a medical doctor?” Only those who answered positively were included. Patients 
of any age could participate. For patients younger than 6 years-old (n=29), a parent filled in 
the questionnaire. Patients with other eczemas included hand eczema, contact dermatitis, and 
general eczema. 
Data were collected through a survey addressing socio-demographic and clinical 
characteristics (family history, diagnosis data, concomitant allergies and treatments) as well 
as Patient Reported Outcomes (PROs) to assess disease severity and QoL. The questions 
were mostly Likert-scale, quantitative questions, yes or no lists, and multiple-choice 
questions.  
 
Study outcomes 
Disease severity was assessed using the Patient Orientated-SCORAD(PO-SCORAD) (range 
score 0 [mild or no disease] to 103 [very severe disease]) scale. Additional,general, and 
disease-specificQoL questionnaires were used, namely the Short Form (SF)-12 (range score 0 
to 100) and the Skindex questionnaires group (range score 0 to 100), previous validated in 
Portuguese [7]1: 
 Skindex-29 for adult population (≥17 years-old); 
 Skindex-teen for the age group between 7 and 16 years-old and; 
 Childhood Atopic Dermatitis Impact Scale (CADIS) for participants with ≤6 years-
old. 
                                                             
1Skindex-teen and CADIS do not have a publish article with their validation results 
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SF-12 is a set of generic, coherent, and easily administered QoL measures, evaluated through 
two dimensions: MCS (Mental Component Summary scores) and PCS (Physical Component 
Summary scores). Higher values correspond to a better QoL[8].  
Regarding Skindex-questionnaires group scores: higher values indicate worse QoL index. 
The following Skindex cut-offs were used: [0-30[, [30-40[, and [40-100] for mild, moderate, 
and severe impact on QoL, respectively [9–12]. In logistic regression analysis, QoL was 
classified in severe impact versus moderate or mild impact, by these cut-offs.  
 
Statistical analysis 
The analysis was made by subgroups: patients with AD and patients with eczema (others). 
All quantitative variables were summarized using descriptive statistics, namely mean or 
median, standard deviation (SD) and range (minimum and maximum). Qualitative variables 
were analysed as absolute (n) and relative frequencies (%). The association between two 
continuous variables was tested with Spearman correlation, and with the Chi-square for 
categorical variables[13]. 
Multiple logistic regression was used to compute adjustedodds ratios (OR) between each 
simultaneous predictor factor and a binary outcome[13]. The multivariable analysis was 
executed with QoL as dependent variable (severe vs non severe impact) controlling for age, 
gender, living place, AD family history, time since diagnosis, exacerbation situations, 
considering having disability, medical appointments frequently, feeling supported by the 
medical community, talking about QoL, social stigma, the PO-SCORAD dimensions, and 
SF-12 dimensions. 
Values of p<0.05 were considered statistically significant and confidence intervals were 
determined with 95% confidence. All analyses were performed using the IBM SPSS 
Statistics 24 for Windows.  
 
Results 
Patients 
A total of 162 participants (n=134 with AD and n=28 with other eczemas), with ages ranging 
from 0.5 to 74 years were included to QUADEP. 
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Sociodemographic and clinical characteristics  
The median age varied between the AD (21.50 years) and eczema (43 years) groups. More 
women (63.4%) were interviewed with AD and the majority live in an urban area (76.9%) 
(Table 1). There are respondents from all Portugal counties, mainly from Lisbon (25.3%), 
followed by Porto (11.7%), Setubal (11.1%), and Santarem (8.6%). Family history of AD 
was observed in 48.5% of AD patients (Table 1). 
Patients from all subgroups were most often diagnosed first by a dermatologist (46.3% for 
AD patients and 50% for eczema patients), followed by a paediatrician (23.9% for AD 
patients) or a General and Family physician (21.6% for AD patients). Another concordance 
seen in both subgroups was the preference for a private institution as place of first diagnosis 
(54.5% for AD patients and 50% for eczema patients) (Table 1).   
Subjects with AD had been diagnosed 11 years ago (median). The average age for AD 
diagnosis was 8.77 years-old. Twenty-five percent of these patients were diagnosed when 
younger than 1 year-old and 15% were 1 year-old when diagnosed (Table 1). 
Concomitant allergic diseases were also studied, and the most common were asthma and/or 
allergic rhinitis.  
A large proportion of AD patients reported their symptoms worsening when they sweat 
(49.3%) (Table 2). Stress moments were described by 11.2% and 3.6% of AD and other 
eczema patients. Concerning “other situations”, 25.4% of AD patients reported: allergen 
contact, wind, when driving (because of hands contact), ironing, sunlight exposure, hot 
weather, certain chemical products, water contact (any temperature), humidity, life changes, 
wool, eating certain foods, when sleeping poorly, using make up, when feeling tired, weather 
changing, close to trees, and physical efforts.  
While 34.1% of subjects with other eczemas described being worse when frequently washing 
their hands, being in contact with pollens/ground/farms, when wearing tight clothing, during 
sports, when  contacting alcoholic disinfectants and detergents, during warm weather, with 
temperature changes, and when in contact with savoury and plants.  
 
Characteristics of care 
Regarding current treatment, many different answers reflect the diversity of therapeutic 
options. Emollients were widely used in both subgroups (85.5% in AD, and 67.9% for other 
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eczemas) (Table 2) and all patients highlighted the importance of daily emollient use to 
improve their QoL. In addition to therapy, 5% of patients reported alternatives to improve 
their lives or to reduce some pain or discomfort, such as montelukast sodium, food 
supplements, folic acid, dietary food and homeopathy and homeopathic creams.  
Regarding discontinued therapies 27.6% AD patients admitted having stopped taking and/or 
using: 
 Immunosuppressors (mainly cyclosporine and azathioprine) due to poor effectiveness 
and adverse events, 
 Oral steroids due to symptoms worsening and adverse events,  
 Topical corticosteroids (TCS) due to poor effectiveness and symptoms worsening, 
 Oral antihistamines due to poor effectiveness, 
 Allergen immunotherapy due to the increase of allergic crises, 
 Some emollients due to poor effectiveness, 
 Antidepressants due to poor effectiveness, 
 Phototherapy, due to poor effectiveness, symptoms worsening and adverse events, 
 Topic tacrolimus due to an intense pruritus, and  
 Acupuncture due to poor effectiveness.  
Apart from the above described treatments, general measures are considered important by 
most patients (76.1% and 42.9% of AD and eczema patients, respectively). Clothing material 
was a concern, with 87.2% of patients preferring cotton and 35.3% reported avoiding wool, 
knitwear, synthetic and acrylic textiles and elastic clothes. Before using something new, some 
patients admitted checking its material, avoiding aggressive seams, turtle necks, and tighter 
clothes, and also removing hang tags. Some patients mentioned the need to use sunglasses 
daily to avoid the wind or going out with light clothing in order to avoid sweating. Some 
patients stated that wearing accessories like belts and details in sandals can be troublesome. 
Regarding bedding, some patients admit to vacuum-cleaning and airing the mattress 
frequently as well as washing the sheets more often and separately from the rest of the 
family, and using specific detergents.  
 
Quality of Life and subjective burden of disease 
In order to understand patients’ perspectives regarding disability, medical support, and 
society rejection, some subjective questions were included (Figure 1). We observed that 
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37.3% of AD patients and 14.3% of other eczema patients consider that their disease causes a 
certain degree of disability. A high number of patients do not attend regular medical 
appointments (29.9% of AD patients and 78.6% of other eczema patients) and some do not 
feel supported by the medical community (22.4% and 35.7%, respectively). A matter of 
concern is how these patients feel about society’s perspective and thought. More than half of 
the AD patients feel stigmatized by society (Figure 1). 
 
As far as score results are concerned, there is some heterogeneity (Table 3). The mean AD 
QoL (Skindex) was 39.68, which represents a moderate impact on QoL. Nevertheless, 44% 
of AD patients report a severe impact on QoL. Patients with more severe disease had a 
greater impact on QoL. “Symptoms” is the most affected category in adults (Table 4).  
In this sample, 87% of AD patients had moderate to severe atopic dermatitis according to PO-
SCORAD (41.8% moderate and 45.5% severe, respectively).  
 
The MCS and PCS results complemented the study of QoL, showing high values that match 
those from Skindex (Table 5). 
 
Factors that can affect QoL 
Regarding the factors that most influenced worse QoL in AD, we found that time since 
diagnosis was statistically related with total score of Skindex (r=0.404; p<0.001) and with 
clinical severity (r=0.324; p<0.001). This implies that QoL worsens over the years and that 
persistent AD is clinically more severe. 
Age was statistically significant associated with severity (r=0.305; p<0.001) and Skindex 
score (r=0.392; p<0.001). With increasing age, the Skindex score is likely to increase (OR: 
1.028 [p=0.007 95%CI 1.008-1.049]). 
Among the situations that can worsen the disease, “dusty areas” and “at night” were the ones 
most associated with Skindex: OR: 2.451 (p=0.025 95%CI 1.118-5.373) and OR: 3.940 
(p=0.006 95%CI 1.490-10.417), respectively. 
“Consider having disability” and feel social stigma” were also associated, OR: 9.349 
(p<0.001 95%CI 4.134-21.146), and OR: 14.857 (p<0.001 95%CI 5.899-37.417), 
respectively.  
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In multivariable analysis, we investigated the associations with worse QoL score between 
some variables. The associationsare reported in Table 6. 
 
Discussion 
This is the first study to provide a comprehensive outlook on the QoL of AD patients in 
Portugal.Since there is still no Portuguese registry for AD, we chose to send the survey 
through post or e-mail, a methodology that has been increasingly used in recent years [14–
16].Doing so, we enrolled 162 patients of varying ages. However, our children’s sample was 
very small and the majority were mild or moderate AD. The three instruments used (Skindex, 
PO-SCORAD and SF-12) were correlated, with statistically significant results. 
The overall mean Skindex score for AD was 39.68 on a 0-100 scale, representing a moderate 
impact on QoL. Since we had a heterogeneous sample comprising mild, moderate, and severe 
AD patients, the mean Skindex score for each severity class was 18.52, 33.09, and 51.57, 
respectively. For adults, “Symptoms” was the dimension with highest score for all subgroups. 
Similarly, among AD teenagers and children, the “Psychosocial functioning” and 
“Symptoms” dimension were the highest scores, respectively. Two previous studies in the 
Netherlands and Australia with patients aged >2 years-old reported a mean Skindex-29 score 
of 39.7 and 58.6 [17, 18].Other previous studies in AD adults revealed a mean Skindex score 
of 20-30, in which “Symptoms” was also the dimension with the highest values [19, 20]. 
Japanese adults reported a mean Skindex-16 score of 50±23 (66±17 among severe disease), 
although the dimension with the highest score was “Emotions”, with a mean score of 64±40 
[21]. “Physical symptoms” is the dimension with the highest values in other studies [22].  
Other instruments are also widely used, such as Dermatology Quality of Life Index (DLQI). 
Nevertheless, the conclusion follows the same path: AD has a strong negative impact on QoL 
and “Symptoms” is the dimension with the strongest impact, whether for adults or children 
[23–27].      
It is known that being a female and with increasing age are risk factors in the appearance of 
eczema and AD[15, 16, 28], as well as environmental factors [29, 30]. This was a convenient 
sample of patients. In a representative sample, we could hypothesize if these factors would 
influence QoL in the same way. Nonetheless, we found that with increasing age, both 
severity (r=0.305; p<0.001) and worst QoL in AD patients (r=0.392; p<0.001) grows worse.  
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Regarding the environmental factor, we did not find any difference amongst patients who live 
in rural and urban areas, perhaps due to our sample being predominantly urban. Nonetheless, 
AD patients, who report being worse when in dusty areas, have 2.451 (p=0.025 95%CI 1.118 
- 5.373) greater chance of having a negative impact on QoL. In addition, AD patients who 
become worse at night presented 3.940 times higher likelihood of a more negative impact on 
QoL. 
As genetics is other important feature concerning the onset of disease, family history is often 
associated with AD or eczema  [16, 31], namely from the mother [32]. Our sample 
corroborates this finding, with 48.5% of AD patients and 32.1% of other eczema patients 
having a positive family history, especially with the mother (33.9% of AD patients). 
When in first contact with the symptoms, patients mostly appeal to a dermatologist, a General 
and Family Physician, or a Paediatrician. Regarding the institution chosen for this appeal, 
patients with AD and other eczemas prefer going to a clinic or private hospital than to a 
public centre. 
This disease can grow worse during childhood or in an adult phase, and as a result, time since 
diagnosis and age of diagnosis can vary. In our subgroups, intervals were observed between 
0.3 and 50 years of diagnosed. Most AD patients were diagnosed when 0-1 years old, and 
still have the disease in adulthood. 
Treatment and therapy efforts are increasingly targeted at reducing disease severity or at 
increasing patients’ QoL [33]. The usual treatments consist of antihistamines, topical and oral 
corticosteroids, and immunosuppressors, amongst others. An important treatment is the 
continuous  use of emollients [28, 34], with 85.8% of AD patients reporting its use, as well as 
67.9% of other eczema patients. Some of these patients described the daily use of emollients, 
shower gel, and shampoo, and that without the emollients their pain is unbearable and 
sometimes cannot even move. A German study also reported emollients  as the most-used 
treatment (by 90.4% of all patients) [24]. Additionally, we verify that 5% of patients reported 
diet changes and other alternatives as treatment, because they saw differences in their disease 
following those changes.  
‘Pharmacological only’ was thought to be marked by patients who only take medication, and 
no emollient, vaccinesor any other ‘self-technique’, as described by many other patients. 
Nevertheless, this topic was not well understood, and some patients signalized 
simultaneously ‘pharmacologic only’ and emollients or others. 
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Responses about treatment, treatment discontinuation, and clothing care allowed us to 
understand how much perseverance these patients have. Apart from the conventional 
treatments, or advice about emollients or clothes to use, they improve their QoL by 
experimenting with what is better or worse for their skin. Our patients reported spending 
around 200€ per month on emollients (moisturizing creams, shampoo, or shower gel). A 
study regarding willingness to pay (in Germany) affirmed that patients with AD would pay 
1000€ per month for sustainable healing  [35]. 
It has previously been shown that society tend to underestimate skin diseases [36].Around 
58% and 46% of patients with AD and eczema, respectively, declared feeling that their 
disease is unappreciated by the society, including some teenagers, who reported suffering 
from bullying at school, which is a known fact among sufferers reported elsewhere [5, 37, 
38]. Also, more than half of patients are not used to talking about QoL with a health 
professional. More data concerning this topic in Portugal is needed. In fact, we observed 
22.4% and 35.7% of AD and other eczema patients do not feel supported by physicians, and 
this may be the reason why some subjects do not have frequent appointments. A previous 
study examined this issue and reported that QoL discussion was absent in 40% of the 
specialist consultations. In appointments where QoL discussion occurred, clinical nurse 
specialists had more dialogue than other clinicians [39].  
We are not the only ones who have found this to be the case.In Japan there is a similar  
realization that AD patients do not usually visit a physician [40]. Assessing the patients’ 
satisfaction with the physician’s care, the mean Visual Analog Scale (VAS) was 59.6, and 
patients with severe disease were satisfied significantly less often [26]. Most of our patients, 
even some of whom did not feel a stigma by society, explained that there exists a lack of 
knowledge and that many questions from or situations with other people make them feel 
uncomfortable. Some such situations have been reported in other studies, confirming a the 
existence of social stigma [27, 38]. 
Patients shared with us some situations that were not questioned:  or instance, that when the 
skin hurts and bleeds, they cannot go to the toilet or take a shower alone; or that when the 
skin is so “rough” that it is awkward to touch/see, or they feel prohibited from taking part in 
enjoyable activities, they are made to feel that they are the ones making things worse.   
In summary, we found some factors that seemed to influence negatively the QoL of patients 
with AD: age and some situations that can worsen the disease, as explained above. In 
addition, patients with worse QoL indexes, also consider that the disease causes disability and 
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also feel the stigma from the society.  
In the multivariable regression models, we can observe that patients who consider having 
disability, with the increased of age, have more area affected by the disease, and more edema 
in the lesions present greater probability of having a severe impact on QoL. Affected body 
surface area was also found to be a predictor factor of worse QoL [35]. 
On the other hand, “consider having disability” is influenced by patients whose disease 
worsens when sweating. Patients with high scores of Skindex and patients with low physical 
score (from SF-12), i.e. negative impact of QoL consider that the disease causes disability. 
Patients whose disease grows worse when sweating and those who feel supported by the 
medical community often have more medical appointments, as well as thosewith a more 
severe disease (high PO-SCORAD score). 
Lastly, considering that the disease causes disability and having frequent medical 
appointments increases the feeling of support. Nonetheless, in our study, patients who do not 
feel the social stigma and having a less severe disease feel more supported by the medical 
community. Being a female is a predictor factor for worse QoL, for patients who do not feel 
supported by the medical community. 
A part of the non-representative sample, other limitation that we can highlight is the fact that 
diagnosis of AD was self-reported for patients, although confirmed by a medical doctor.   
Although our study focused on the patient perspective, there is evidence that the correlations 
between patient and physician perspective are not very different [23]. Since this is the first 
study that describes the AD’s QoL in Portugal, we elected to listen, firstly, to the patients. 
However, a great deal remains to be done, regarding future studies and actions in the country. 
As noted above, it is important to assess the patient-physician relationship in order to include 
the patient more in the decisions regarding treatment and life-style. These patients have 
enormous perseverance. There is wide heterogeneity amongst severity, affected areas, and 
conditions that worsen the disease. These diseases have a daily variance pattern and it is 
important to listen more to the patients since they are the ones who know the disease’s 
behaviour best. To improve QoL, the focus should not be on the treatment only, but also on 
the “techniques” patients already know and employ, such as choices about clothing, cleaning, 
emollients, showers, etc. In addition, it is important to have more awareness-raising activities, 
in order to educate society, decrease the stigma and in consequences, and to help some of the 
factors affecting the psychological well-being of patients with AD and eczema.  
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Tables 
Table 1: Sociodemographic and clinical characteristics concerning atopic dermatitis and 
other eczemas 
 Atopic Dermatitis 
(n=134) 
Other eczemas 
(n=28) 
Age, years   
Median [min-max] 21.50 [0.5-74] 43.00 [9-59] 
0-6 years, n (%) 29 (21.6) 0 (0.0) 
7-16 years, n (%) 28 (20.9) 3 (10.7) 
17-29 years, n (%) 35 (26.1) 6 (21.4) 
30-39 years, n (%) 14 (10.4) 3 (10.7) 
40-49 years, n (%) 14 (10.4) 7 (25.0) 
50-59 years, n (%) 8 (6.0) 9 (32.1) 
60-80 years, n (%) 6 (4.5) 0 (0.0) 
Feminine, n (%) 85 (63.4) 11 (39.3) 
Urban, n (%) 103 (76.9) 19 (67.9) 
AD Family history, n (%) 65 (48.5) 9 (32.1) 
Mother 22 (33.9) 1 (11.1) 
Father 14 (21.5) 1 (11.1) 
Grandparents and grandchildren 6 (9.2) 2 (22.2) 
Children 13 (20.0) 2 (22.2) 
Siblings 14 (21.5) 4 (44.4) 
Nephews, cousins and uncle/aunts 12 (18.5) 0 (0.0) 
Further Relatives 2 (3.08) 1 (11.1) 
Medical speciality which diagnosed, n (%)   
General and Family Physician 29 (21.6) 9 (32.1) 
Immunoalergologist 8 (6.0) 2 (7.1) 
Dermatologist 62 (46.3) 14 (50) 
Paediatric 32 (23.9) 2 (7.1) 
Other 3 (2.2)a 1 (3.6)b 
Health centre where diagnosis occurred, n (%)   
Public Hospital 30 (22.4) 3 (10.7) 
Private clinic/hospital  73 (54.5) 14 (50.0) 
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Primary Care 29 (21.6) 10 (35.7) 
Other 1 (0.7)d 0 (0.0) 
Time since diagnosis, n (%)   
Median [min-max] 11.00 [0.3-50] 6.00 [1-40] 
<1 years, n (%) 8 (6.0) 4 (14.3) 
2-5 years, n (%) 32 (23.9) 9 (32.1) 
6-10 years, n (%) 22 (16.4) 4 (14.3) 
>11 years, n (%) 66 (49.3) 9 (32.1) 
Age when diagnosis, years   
Mean ± SD 8.77 ± 12.41 27.69 ± 15.70 
Other allergic disease, n (%) 59 (44.0) 1 (3.6) 
Asthma  9 (15.3) 0 (0.0) 
Rhinitis 22 (37.3) 1 (100.0) 
Asthma and Rhinitis 4 (6.8) 0 (0.0) 
Sinusitis  3 (5.1) 0 (0.0) 
Combinations  8 (13.6) 0 (0.0) 
Others  13 (22.0) 0 (0.0) 
a pharmacist, internal medicine and oncologist 
b emergency 
c pharmacist/pharmacy, emergency room, occupational medicine 
d  pharmacy  
SD: standard deviation 
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Table 2: Treatment characteristics and characteristics of care concerning atopic dermatitis 
and other eczemas 
 Atopic Dermatitis 
(n=134) 
Other eczemas 
(n=28) 
Exacerbation situations, n (%)   
Winter 49 (36.6) 7 (25.0) 
Spring 55 (41.0) 6 (21.4) 
Summer 42 (31.3) 4 (14.3) 
Autumn 31 (23.1) 2 (7.1) 
Animals 31 (23.1) 2 (7.1) 
Dusty areas 42 (31.3) 6 (21.4) 
At night 26 (14.4) 1 (3.6) 
Sweat  66 (49.3) 3 (10.7) 
Stress moments 15 (11.2) 1 (3.6) 
Does not exist/Does not know  10 (7.5) 5 (17.9) 
Other 34 (25.4) 9 (34.1) 
Allergy tests, n (%)  86 (64.2) 3 (10.7) 
Blood tests  59 (68.6) 2 (66.7) 
Skin prick test 65 (75.6) 3 (100.0) 
Patch test 28 (32.6) 0 (0.0) 
Results, n (%)   
Mites 53 (61.6) 1 (33.3) 
Pollen 45 (52.3)  1 (33.3) 
Food 28 (32.6) 0 (0.0) 
Fungi 10 (11.6)  0 (0.0) 
Animals 32 (37.2) 1 (33.3) 
Bug bite 9 (10.5) 0 (0.0) 
Drugs 10 (11.6) 0 (0.0) 
Other 18 (20.9) 2 (66.7) 
Current treatment, n (%)   
Pharmacological only 8 (6.0) 1 (3.6) 
Antihistamines 73 (54.5) 2 (7.1) 
Emollients  115 (85.8) 19 (67.9) 
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Immunotherapy 11 (8.2) 0 (0.0) 
Corticoids (topical or systemic) 86 (64.2) 15 (53.6) 
Immunosuppressants 14 (10.4) 0 (0.0) 
None  2 (1.49) 3 (1.85) 
Others  7 (5.22) 0 (0.0) 
Treatment discontinuation, n (%)  37 (27.6) 2 (7.1) 
Clothing care, n (%) 102 (76.1)  12 (42.9) 
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Table 3: Skindex and PO-SCORAD results and respective correlations by disease subgroup 
  Skindex Total score 
Atopic 
Dermatitis 
Disease severity* Mild (n=17) Moderate (n=56) Severe (n=61) Overall (n=134) 
Mean ± SD 18.52 ± 8.81 33.09 ± 16.68 51.57 ± 18.95 39.68 ± 20.66 
Spearman coefficient 0.661 a 
Other 
Eczemas 
Disease severity*
 
Mild (n=7)
 
Moderate (n=17)
 
Severe (n=4)
 
Overall (n=28) 
Mean ± SD 17.03 ± 3.87 30.35 ± 10.15 41.81 ± 18.68 28.66 ± 12.87 
Spearman coefficient 0.672 a 
* 
measured by PO-SCORAD score, based on [0-25[, [25-50[, and ≥50, which represent levels of mild, moderate and severe, 
respectively. 
a p≤0.001 
SD: Standard deviation  
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Table 4: Skindex-29, Skindex-teen and CADIS dimensions by disease subgroup 
 Atopic Dermatitis 
(n=134) 
Other eczemas 
(n=28) 
Skindex-29, Functioning dimension score N=77 N=25 
Mean ± SD 35.10 ± 24.00 16.58 ± 14.54 
Skindex-29, Emotions dimension score N=77 N=25 
Mean ± SD 46.74 ± 22.18 33.72 ± 16.04 
Skindex-29, Symptoms dimension score N=77 N=25 
Mean ± SD 62.78 ± 15.99 47.29 ± 14.18 
Skindex–teen, PS dimension score N=28 N=3 
Mean ± SD 53.75 ± 16.59 35.0 ± 10.0 
Skindex–teen, PF dimension score N=28 N=3 
Mean ± SD 31.34 ± 22.49 47.29 ± 14.18 
CADIS, Family dimension score N=29  
Mean ± SD 15.8 ± 20.41 - 
CADIS, Emotions dimension score N=29  
Mean ± SD 27.99 ± 18.40 - 
CADIS, Sleep dimension score N=29  
Mean ± SD 17.82 ± 21.48 - 
CADIS, Symptoms dimension score N=29  
Mean ± SD 42.86 ±26.11 - 
CADIS, Activities dimension score N=29  
Mean ± SD 22.74 ± 17.98 - 
NA: Not applicable; PF: Psychosocial functioning; PS: Physical symptoms; SD: standard deviation 
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Table 5: Correlations between Skindex or PO-SCORAD and SF-12, by disease subgroup 
  MCS PCS 
Atopic 
dermatitis 
PO-SCORAD Spearman coefficient=-0.265 a Spearman coefficient=-0.453 b 
Skindex Spearman coefficient=-0.451 b Spearman coefficient=-0.337 b 
Other 
eczemas 
PO-SCORAD
 Spearman coefficient=-0.369 Spearman coefficient=-0.377 a 
Skindex
 Spearman coefficient=-0.349 Spearman coefficient=-0.385 a 
a p≤0.05 
b p≤0.001 
MCS: Mental Component Summary scores; PCS: Physical Component Summary scores 
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Table 6: Multivariable logistic regression for AD 
Predictor 
variables 
Skindex a 
Predictor 
variables 
Disability b 
Predictor 
variables 
Having medical 
appointments c 
Predictor 
variables 
Feeling 
supported d 
 
Atopic 
dermatitis 
 
Atopic 
dermatitis 
 
Atopic 
dermatitis 
 
Atopic 
dermatitis 
Age 
(95%IC) 
OR: 1.03* 
(1.00-1.06) 
Disease 
getting worst 
when sweat 
(95%IC) 
OR: 3.50* 
(1.22-10.07) 
Disease 
getting worst 
when sweat 
(95%IC) 
OR: 3.51* 
(1.36-9.03) 
Considering 
disability 
(95%IC) 
OR: 10.73* 
(2.07-55.62) 
Considering 
disability 
(95%IC) 
OR: 6.72** 
(2.56-17.63) 
Skindex 
Total score 
(95%IC) 
OR: 1.07** 
(1.03-1.10) 
Feeling 
supported by 
medical 
community 
(95%IC) 
OR: 21.55**  
(6.38-72.81) 
Having 
medical 
appointments 
(95%IC) 
OR: 48.09** 
(8.10-257.05) 
Affected  
area  
(95%IC) 
OR: 1.07** 
(1.03-1.11) 
PCS 
(95%IC) 
OR: 0.91* 
(0.85-0.97) 
Final score 
of PO-
SCORAD 
(95%IC) 
OR: 1.05** 
(1.02-1.09) 
Feeling 
depreciation 
by society 
(95%IC) 
OR: 0.147* 
(0.03-0.76) 
Edema  
(95%IC) 
OR: 2.04* 
(1.23-3.40) 
    Final score 
of PO-
SCORAD 
(95%IC) 
OR: 0.89** 
(0.83-0.94) 
      Gender 
(95%IC) 
OR: 0.21* 
(0.05-0.85) 
      Disease 
getting worst 
at Winter 
(95%IC) 
OR: 0.13* 
(0.03-0.53) 
      Disease 
getting worst 
at Autumn 
(95%IC) 
OR: 5.03* 
(1.01-25.09) 
      Disease 
getting worst 
when sweat 
(95%IC) 
OR: 0.25* 
(0.07-0.91) 
ROC curve  
(95%IC) 
Area: 0.867** 
 (0.801-0.934) 
 Area: 0.865** 
(0.789-0.941) 
 Area: 0.818** 
(0.741-0.895) 
 Area: 0.924** 
(0.875-0.972) 
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(**p≤0.001; *p≤0.05) 
a dependent variable is Skindex Score (1=Severe Score, 0=Little, Mild and Moderate Score) 
b dependent variable is disability (1=Yes, 0=No) 
c dependent variable is having medical appointments (1=Yes, 0=No) 
d dependent variable is Feeling supported (1=Yes, 0=No) 
Independent variables were: age, affected area, edema, elimination of liquid/crusts, Skindex Total Score, PO-SCORAD score, PCS and 
MCS as continuous variables; and disability, disease getting worst, feeling supported, having medical and feeling depreciation by 
society with reference: no 
MCS: Mental Component Summary scores OR: Odds Ratio; PCS: Physical Component Summary scores; ROC: Receiver operating 
characteristic 
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Figures 
 
Figure 1: Patients’ perspective regarding disability, medical support and society depreciation by disease subgroup  
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